CN116712507A - Traditional Chinese medicine composition for assisting breast cancer chemotherapy and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for assisting breast cancer chemotherapy and preparation method and application thereof Download PDFInfo
- Publication number
- CN116712507A CN116712507A CN202311000052.4A CN202311000052A CN116712507A CN 116712507 A CN116712507 A CN 116712507A CN 202311000052 A CN202311000052 A CN 202311000052A CN 116712507 A CN116712507 A CN 116712507A
- Authority
- CN
- China
- Prior art keywords
- parts
- breast cancer
- chemotherapy
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 81
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 53
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 18
- 241000545744 Hirudinea Species 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 16
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 13
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 6
- 230000001629 suppression Effects 0.000 claims abstract description 6
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 4
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 19
- 241001106477 Paeoniaceae Species 0.000 claims description 17
- 235000006533 astragalus Nutrition 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 15
- 241001289529 Fallopia multiflora Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 241000045403 Astragalus propinquus Species 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 241000005787 Cistanche Species 0.000 claims description 9
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 241000336291 Cistanche deserticola Species 0.000 claims description 6
- 241001061264 Astragalus Species 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 244000001632 Acorus gramineus Species 0.000 claims description 3
- 235000013073 Acorus gramineus Nutrition 0.000 claims description 3
- 241000237903 Hirudo Species 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 2
- 230000036737 immune function Effects 0.000 abstract description 10
- 241000336315 Cistanche salsa Species 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 229940107666 astragalus root Drugs 0.000 abstract description 2
- 201000002364 leukopenia Diseases 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 16
- 238000010586 diagram Methods 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000004820 blood count Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010201 enrichment analysis Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004879 molecular function Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention is applicable to the technical field of medicines, and provides a traditional Chinese medicine composition for assisting breast cancer chemotherapy, which comprises the following raw materials in parts by weight: astragalus root, cistanche salsa, glossy privet fruit, rhizoma polygonati, leech, grassleaf sweelflag rhizome, red paeony root, prepared tuber fleeceflower root and honey-fried licorice root. The invention also provides a preparation method of the traditional Chinese medicine composition for assisting breast cancer chemotherapy. The invention also provides an application of the traditional Chinese medicine composition for assisting breast cancer chemotherapy in preparing medicines for improving the effective rate of breast cancer new auxiliary chemotherapy, reducing bone marrow suppression and improving immune function. The invention can improve the effective rate of the breast cancer new auxiliary chemotherapy, can improve the serum total protein level, and has obvious improvement on leucopenia caused by radiotherapy and chemotherapy.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine composition for assisting breast cancer chemotherapy, and a preparation method and application thereof.
Background
Breast cancer is the malignant tumor with the highest incidence rate of women worldwide, and the new auxiliary chemotherapy of breast cancer has been widely applied to the clinical treatment of locally advanced breast cancer, and the clinical application of the new auxiliary chemotherapy of breast cancer has the advantages of not being limited by the size of the tumor, facilitating the operation of the tumor in a period of time reduction, changing the tumor shrinkage into breast retaining operation and the like, and the new auxiliary chemotherapy can improve the overall survival time of patients and improve the life quality. The clinical proposal of docetaxel, carboplatin, paclitaxel, anthracycline and the like is often used as the main proposal of new auxiliary chemotherapy of breast cancer, which can promote the conversion of the breast cancer which cannot be operated into the surgical treatment by reducing the tumor volume and the transferred axillary lymph nodes, but the clinical discovery of the new auxiliary chemotherapy has a certain limitation, and patients often have poor tolerance caused by serious adverse reactions (bone marrow suppression, immunosuppression and the like) of chemotherapy drugs, thereby stopping the chemotherapy and affecting the overall treatment of the breast cancer. In recent years, traditional Chinese medicine has been developed in the treatment of breast cancer patients, but has not had a clear breakthrough.
Therefore, how to improve the chemotherapy effect and reduce the adverse reaction of the chemotherapy drugs and the bone marrow suppression of chemotherapy and improve the NK activity and the immune function of natural killer cells together with a new auxiliary chemotherapy scheme is the dilemma of the prior breast cancer treatment.
Disclosure of Invention
The embodiment of the invention aims to provide a traditional Chinese medicine composition for assisting breast cancer chemotherapy, and aims to solve the problems in the background technology.
The embodiment of the invention is realized in such a way that the traditional Chinese medicine composition for assisting breast cancer chemotherapy comprises the following raw materials in parts by weight: 45-55 parts of astragalus membranaceus, 10-15 parts of cistanche deserticola, 10-20 parts of wine glossy privet fruit, 10-20 parts of rhizoma polygonati, 6-10 parts of leech, 10-20 parts of rhizoma acori graminei, 10-15 parts of red paeony root, 10-15 parts of prepared polygonum multiflorum and 6-10 parts of honey-fried licorice root.
Preferably, the feed comprises the following raw materials in parts by weight: 50-55 parts of astragalus membranaceus, 12-15 parts of cistanche deserticola, 15-20 parts of wine glossy privet fruit, 15-20 parts of rhizoma polygonati, 8-10 parts of leech, 15-20 parts of rhizoma acori graminei, 10-12 parts of red paeony root, 10-12 parts of prepared polygonum multiflorum and 6-8 parts of honey-fried licorice root.
Preferably, the feed comprises the following raw materials in parts by weight: 50 parts of astragalus, 15 parts of cistanche, 20 parts of wine glossy privet fruit, 20 parts of rhizoma polygonati, 10 parts of leech, 15 parts of grassleaf sweetflag rhizome, 10 parts of red paeony root, 10 parts of prepared tuber fleeceflower root and 6 parts of honey-fried licorice root.
Another object of the embodiment of the present invention is to provide a method for preparing a traditional Chinese medicine composition for assisting breast cancer chemotherapy, comprising the following steps:
mixing rhizoma Acori Graminei, pulverizing, and sieving to obtain rhizoma Acori Graminei powder;
soaking radix astragali, herba cistanches, fructus Ligustri Lucidi, rhizoma Polygonati, hirudo, radix Paeoniae Rubra, radix Polygoni Multiflori Preparata, and radix Glycyrrhizae Preparata in water, decocting twice, mixing the decoctions, concentrating under reduced pressure to soft extract, and drying under reduced pressure to obtain dry extract;
mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving.
Preferably, in the step of soaking astragalus, cistanche, glossy privet fruit, rhizoma polygonati, leech, red paeony root, prepared polygonum multiflorum and honey-fried licorice root in water, the soaking time is 0.5-1h.
Preferably, in the two steps of decoction, 8-15 times of water is added in the first decoction, the decoction is carried out for 1.5-2 hours, and 6-12 times of water is added in the second decoction, and the decoction is carried out for 1.5-2 hours.
Preferably, in the step of concentrating under reduced pressure to a thick paste, the temperature of the reduced pressure concentration is 50-60 ℃, and the relative density of the thick paste is 1.25-1.4.
Preferably, in the step of drying under reduced pressure to obtain a dry paste, the temperature of the drying under reduced pressure is 60-80 ℃.
Another object of the embodiment of the invention is to provide an application of a traditional Chinese medicine composition for assisting breast cancer chemotherapy in preparing medicines for improving the effective rate of breast cancer new assisting chemotherapy, reducing bone marrow suppression and improving immune function.
The traditional Chinese medicine composition for assisting breast cancer chemotherapy provided by the embodiment of the invention aims at the pathogenesis and clinical experience selection formula of a patient with breast cancer new assisting chemotherapy, the traditional Chinese medicine belongs to the category of 'breast rock', and is poor in healthy qi, qi movement and evacuation disorder cause spleen and stomach transportation and unsmooth body fluid and blood circulation, spleen is not healthy, and water transportation disorder causes phlegm dampness to grow internally; kidney essence deficiency and malnutrition of the breast; the spleen deficiency and kidney deficiency, blood stasis and phlegm coagulation are formed into toxin for a long time, the focus of the pathogenesis is the deficiency of qi and yin and yang of viscera, the deficiency is the deficiency of qi and yin and yang of viscera, the excess is the blood stasis and phlegm turbidity is agglomerated and agglomerated, marrow inhibition caused by chemotherapy is the accumulation of toxin in evil, qi consumption and blood consumption are involved, viscera are injured, kidney essence and spleen transportation and transformation functions are seriously influenced, spleen is not healthy and transportation is carried out, qi and blood are biochemically passive, thus the main pathogenesis of a patient with breast cancer is qi deficiency, kidney deficiency, blood stasis and phlegm turbidity in a new auxiliary chemotherapy, the traditional Chinese medicine composition provided by the embodiment of the invention can benefit qi and spleen, tonify kidney and essence, eliminate dampness and phlegm, improve kidney deficiency and qi deficiency symptoms, has the action mechanism mainly to improve liver glycogen reserve, improve hematopoiesis and immunity, is likely to exert anti-tumor effect by improving the activity of NK cells, promoting T lymphocyte proliferation and differentiation, and improving the effective auxiliary chemotherapy efficiency of breast cancer, and can improve the total protein level of serum and obviously improve leucopenia caused by radiotherapy and chemotherapy.
Drawings
FIG. 1 is a Wen diagram provided by an embodiment of the present invention;
FIG. 2 is a PPI network diagram derived from a string website provided by an embodiment of the present invention;
FIG. 3 is a PPI network diagram drawn by cytoscape software provided by an embodiment of the present invention;
FIG. 4 is a topology analysis chart provided by an embodiment of the present invention;
FIG. 5 is a diagram of a component-disease target network provided by an embodiment of the present invention;
FIG. 6 is a KEGG pathway enrichment analysis graph provided by an embodiment of the invention;
FIG. 7 is a diagram of a component-disease-pathway-target network provided by an embodiment of the invention.
Detailed Description
The present invention will be described in further detail with reference to the drawings and examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
A Chinese medicinal composition for assisting breast cancer chemotherapy, its preparation method comprises the following steps:
(1) Mixing rhizoma Acori Graminei, pulverizing to 80 mesh;
(2) Soaking radix astragali, herba cistanches, fructus Ligustri Lucidi, rhizoma Polygonati, hirudo, radix Paeoniae Rubra, radix Polygoni Multiflori Preparata, and radix Glycyrrhizae Preparata in water for 0.5 hr, decocting for 1.5-2 hr each time, adding 8-15 times of water for the first time and 6-12 times of water for the second time, filtering, mixing decoctions, concentrating under reduced pressure at 50-60deg.C to obtain soft extract with relative density of 1.25-1.4, and drying under reduced pressure at 60-80deg.C to obtain dry extract;
(3) Mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving with 60 mesh sieve;
the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 45-55 parts of astragalus membranaceus, 10-15 parts of cistanche deserticola, 10-20 parts of wine glossy privet fruit, 10-20 parts of rhizoma polygonati, 6-10 parts of leech, 10-20 parts of rhizoma acori graminei, 10-15 parts of red paeony root, 10-15 parts of prepared polygonum multiflorum and 6-10 parts of honey-fried licorice root;
the preferable formula is as follows: 50 parts of astragalus, 15 parts of cistanche, 20 parts of wine glossy privet fruit, 20 parts of rhizoma polygonati, 10 parts of leech, 15 parts of grassleaf sweetflag rhizome, 10 parts of red paeony root, 10 parts of prepared tuber fleeceflower root and 6 parts of honey-fried licorice root.
Specific implementations of the invention are described in detail below in connection with specific embodiments.
Embodiment 1, a traditional Chinese medicine composition for assisting breast cancer chemotherapy, the preparation method comprises the following steps:
(1) Mixing 15g of rhizoma acori graminei, and crushing to 80 meshes for standby;
(2) Soaking 50g of astragalus membranaceus, 15g of cistanche salsa, 20g of wine glossy privet fruit, 20g of rhizoma polygonati, 10g of leech, 10g of red paeony root, 10g of prepared polygonum multiflorum and 6g of prepared liquorice in water for 0.5h, decocting for 2h each time, adding 12 times of water for the first time and 10 times of water for the second time, filtering, combining the two decoctions, concentrating under reduced pressure at 60 ℃ to thick paste with the relative density of 1.25-1.4, and drying under reduced pressure at 80 ℃ to obtain dry paste for later use;
(3) Mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving with 60 mesh sieve.
The performance effect of the traditional Chinese medicine composition prepared in the example 1 is verified, and the performance effect is verified specifically as follows:
case:
all study subjects were derived from post-operative breast cancer patients with complete data of cases from 11 months 2018 to 1 month 2023, and 60 patients were randomized into two groups according to the random number table method:
new adjuvant chemotherapy group 30 cases: age 18-69 years, average (47.83±8.53) years; stage IIB 4, stage IIIA 15, stage IIIB 9 and stage IIIC 2; 11 cases of invasive lobular carcinoma, 16 cases of invasive catheter carcinoma, 1 case of papillary carcinoma, 1 case of medullary carcinoma and 1 case of mucinous adenocarcinoma among tumor pathology types; average tumor diameter (2.97.+ -. 0.68) cm; puncture pathology her-2 positive 16 cases, three negative 14 cases;
traditional Chinese medicine + neoadjuvant chemotherapy group 30 cases: age 18-69 years, average (45.20±9.61) years; stage IIB 3, stage IIIA 15, stage IIIB 8 and stage IIIC 4 in the disease stage; 12 cases of invasive lobular carcinoma, 14 cases of invasive catheter carcinoma, 1 case of papillary carcinoma, 2 cases of medullary carcinoma and 1 case of mucinous adenocarcinoma among tumor pathology types; average tumor diameter (3.02.+ -. 0.64) cm; puncturing pathology her-2 positive 15 cases and three negative 15 cases;
the general data of age, disease stage, pathology type and the like between the two groups are compared without statistical difference (P is more than 0.05), so that the two groups are comparable;
general data comparison of two groups of patients suffering from chemotherapy cancer induced fatigue (CRF) of breast cancer) As shown in table 1:
TABLE 1
Inclusion criteria:
(1) The postoperative pathology diagnosis is that the breast cancer is in the I-III phase of the non-tumor state after the operation;
(2) The Western medicine treatment scheme is adopted to assist chemotherapy according to the line standard Fan Xin of the national cancer institute (China anticancer Association) breast cancer diagnosis and treatment guide and Specification): triple negative breast cancer with lymph node positive or tumor exceeding 2 cm; and human epidermal growth factor receptor 2 (HER 2) positive breast cancer patients with high risk factors of lymph node positive or lymph node negative.
(3) ECOG score: 0-1 min;
(4) Survival is expected to be greater than 9 months.
Exclusion criteria:
(1) Patients who are treated with drugs other than immunotherapy or chemotherapy that have an effect on immune indicators;
(2) Patients with other severe somatic diseases;
(3) Patients with mental history or intellectual disabilities in the past;
(4) The drug, alcohol and drug dependence;
(5) Cerebral metastasis;
(6) Those with electrolyte disorders;
(7) Patients with anemia of singleness are excluded.
The treatment method comprises the following steps:
chemotherapy group: HER-2 positive patients use HP in combination with taxanes and platinum drug regimens; the her-2 negative application of the yew medicine combined with the platinum medicine has 1 treatment course in 21 days and 4 treatment courses in observation period;
traditional Chinese medicine + chemotherapy group: the group of cases is treated by the traditional Chinese medicine composition of the embodiment 1 on the basis of a chemotherapy group, and is continuously taken from 5 days before chemotherapy, 2 times a day (before breakfast and after supper), 1 course of treatment is 21 days, and 4 courses of treatment are taken altogether.
And (3) observing the indexes:
curative effect judgment criteria: complete alleviation of CCR: the tumor body diameter is reduced by more than 70 percent, no new focus is found and the tumor body is maintained for more than 1 month; partial Relief (PR): the tumor body diameter is reduced by 40-70%, no new focus is found and maintained for more than 1 month; disease Stabilization (SD): the diameter of the tumor body is reduced below 40 percent or has no obvious change; disease Progression (PD) maximum tumor diameter increase or new lesions appear, with total effective rate of (cr+pr) cases total number x 100%;
evaluation of immune condition efficacy: all patients were treated with cycle 1 chemotherapy followed by cycle 4 chemotherapy with 5ml peripheral blood drawn from the 3 rd sky abdomen and the percentage of lymphocyte subpopulations (cd3+, cd4+, cd8+, NK) in the peripheral blood was measured using a flow cytometer to assess immune function;
white blood cell count change: the patient was examined for white blood cell count by drawing 5ml of peripheral blood from the sky-abdomen at 7 days and 14 th sky-abdomen after the end of the 4 th cycle of chemotherapy (white blood cell normal reference value is 3.5-10×10) 9 /L）；
Safety index: during the treatment period, observing whether the patient has skin rash, nausea, diarrhea and other adverse events, analyzing reasons, judging whether the patient is related to traditional Chinese medicines, and monitoring the conventional blood and urine and liver and kidney functions; determining the electrocardiogram of the patient, and reflecting the occurrence of the adverse event by applying the occurrence rate of the adverse event;
the statistical method comprises the following steps: statistical analysis is performed by SPSS21.0 software, and the continuity variable is checked for normality by the Shapiro-Wilk method, and the normal distribution is metThe method is characterized in that a t test is used for statistical analysis, if normal distribution is not met, M (P25, P75) is used for description, a rank and test is used for statistical analysis, fisher's exact probability method is used for comparing the difference of counting data, repeated measurement variance analysis is adopted for the data of a front strategy and a rear strategy, covariance method is adopted for controlling confounding factors, and the test level is as follows: with P<0.05 is significant for the difference between the two.
Results:
(1) Comparison of clinical efficacy in two groups of patients: the total effective rate of the observed group was 83.33%, significantly higher than that of the control group, and the differences were statistically significant, as shown in table 2:
TABLE 2
(2) Comparison of immune function indicators for two groups of patients: through the Shapiro-Wilk normal test, the traditional Chinese medicine + chemotherapy group and the chemotherapy group CD3+ accord with normal distribution (P > 0.05) before and after treatment, and the rest do not accord with normal distribution (P < 0.05); the ratio of CD3+, CD4+ and NK of the traditional Chinese medicine and chemotherapy group is obviously increased compared with the ratio before chemotherapy, the ratio of CD8+ is obviously reduced compared with the ratio before chemotherapy, and the intra-group comparison has statistical significance (P < 0.05); the CD3+, CD4+ and NK ratio of the chemotherapy group are obviously reduced compared with the chemotherapy before, the CD8+ ratio is increased compared with the chemotherapy before, and the intra-group comparison has statistical significance (P < 0.05); comparison of cd3+, cd4+, NK ratios and cd8+ ratios between the two groups after treatment was statistically significant (P < 0.001), as shown in table 3, table 4, table 5:
TABLE 3 comparison of CD3+ before and after chemotherapy for two groups）
TABLE 4 CD4+, CD8+ comparison (M (P25, P75)) before and after treatment of two groups
TABLE 5 comparison of NK before and after treatment (M (P25, P75))
(3) White blood cell count comparison before and after treatment of two groups of patients: the single sample rank and test results show that the white blood cell count comparison of the two groups of patients on the 7 th day after the 4 th period chemotherapy is reduced, and the difference has no statistical significance (PSEATMENT=0.964, PSOYTRICH=0.057); the white blood cell count of both groups of patients was significantly increased (P < 0.05) after 14 days of chemotherapy compared to 5 days of chemotherapy, and the traditional Chinese medicine + chemotherapy group was significantly increased (P < 0.05), as shown in table 6:
table 6 white blood cell count (x 10) after treatment of both groups 9 /L)（M(P25,P75)）
Adverse reaction: after treatment, the two groups of subjects have routine blood, urine and stool, and no obvious abnormality exists in renal function and electrocardiographic examination; in the treatment period, 2 cases of traditional Chinese medicine and chemotherapy groups and 3 cases of chemotherapy groups are all subjected to liver function injury (mainly comprising glutamic pyruvic transaminase rise) on day 5 after chemotherapy, transaminase falls to a normal range 3-5 days after application of liver protection drugs, and the adverse reaction rates of the traditional Chinese medicine and chemotherapy groups and the chemotherapy groups are respectively 3.3% (1/30) and 10% (3/30), wherein the difference between the two groups has no statistical significance (P is more than 0.05).
In conclusion, the novel adjuvant chemotherapy effect of the traditional Chinese medicine and the chemotherapy group is obviously better than that of the chemotherapy group, the recovery condition of the white blood cell count after chemotherapy is also obviously better than that of the chemotherapy group, the immune function of a patient in the chemotherapy group is obviously inhibited, however, the immune function of the traditional Chinese medicine and the chemotherapy group is improved, which shows that the traditional Chinese medicine composition prepared in the embodiment 1 not only corrects the state of low immune function of the patient after chemotherapy, but also can obviously improve the immune function of the patient, and the traditional Chinese medicine composition has definite curative effect on resisting breast cancer, can improve the immune function state of the patient after breast cancer, prevents the suppression of the bone marrow after chemotherapy to a certain extent, has unique advantages in adjuvant therapy of breast cancer, has definite curative effect, and can be clinically popularized and applied.
Embodiment 2, a traditional Chinese medicine composition for assisting breast cancer chemotherapy, the preparation method comprises the following steps:
(1) Mixing 10g of rhizoma acori graminei, and crushing to 80 meshes for standby;
(2) Taking 45g of astragalus membranaceus, 10g of cistanche salsa, 10g of wine glossy privet fruit, 10g of rhizoma polygonati, 6g of leech, 10g of red paeony root, 10g of prepared polygonum multiflorum and 6g of honey-fried licorice root, soaking in water for 0.5h, decocting twice, 1.5h each time, adding 8 times of water for the first time, adding 6 times of water for the second time, filtering, combining the two decoctions, concentrating under reduced pressure at 50 ℃ to thick paste with the relative density of 1.25-1.4, and drying under reduced pressure at 60 ℃ to obtain dry paste for later use;
(3) Mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving with 60 mesh sieve.
Embodiment 3, a Chinese medicinal composition for assisting breast cancer chemotherapy, the preparation method comprises the following steps:
(1) Mixing 15g of rhizoma acori graminei, and crushing to 80 meshes for standby;
(2) Soaking 50g of astragalus membranaceus, 12g of cistanche salsa, 15g of wine glossy privet fruit, 15g of rhizoma polygonati, 8g of leech, 10g of red paeony root, 10g of prepared polygonum multiflorum and 6g of prepared liquorice in water for 0.5h, decocting for 2h each time, adding 10 times of water for the first time, adding 10 times of water for the second time, filtering, combining the two decoctions, concentrating under reduced pressure at 55 ℃ to thick paste with the relative density of 1.25-1.4, and drying under reduced pressure at 70 ℃ to obtain dry paste for later use;
(3) Mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving with 60 mesh sieve.
Embodiment 4, a traditional Chinese medicine composition for assisting breast cancer chemotherapy, the preparation method comprises the following steps:
(1) Mixing 20g of rhizoma acori graminei, and crushing to 80 meshes for standby;
(2) Taking 55g of astragalus membranaceus, 15g of cistanche salsa, 20g of wine glossy privet fruit, 20g of rhizoma polygonati, 10g of leech, 12g of red paeony root, 12g of prepared polygonum multiflorum and 8g of prepared liquorice, soaking in water for 0.5h, decocting twice, 1.5h each time, adding 12 times of water for the first time, adding 12 times of water for the second time, filtering, combining the two decoctions, concentrating under reduced pressure at 60 ℃ to thick paste with the relative density of 1.25-1.4, and drying under reduced pressure at 80 ℃ to obtain dry paste for later use;
(3) Mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving with 60 mesh sieve.
Embodiment 5, a traditional Chinese medicine composition for assisting breast cancer chemotherapy, the preparation method comprises the following steps:
(1) Mixing 20g of rhizoma acori graminei, and crushing to 80 meshes for standby;
(2) Taking 55g of astragalus membranaceus, 15g of cistanche salsa, 20g of wine glossy privet fruit, 20g of rhizoma polygonati, 10g of leech, 15g of red paeony root, 15g of prepared polygonum multiflorum and 10g of honey-fried licorice root, soaking in water for 0.5h, decocting twice, 1.5h each time, adding 15 times of water for the first time, adding 12 times of water for the second time, filtering, combining the two decoctions, concentrating under reduced pressure at 60 ℃ to thick paste with the relative density of 1.25-1.4, and drying under reduced pressure at 80 ℃ to obtain dry paste for later use;
(3) Mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving with 60 mesh sieve.
The molecular mechanism of the traditional Chinese medicine for treating breast cancer in the embodiment of the invention is verified by using network pharmacology, and the molecular mechanism is specifically as follows:
(1) Inquiring component target information:
retrieving the compound components and targets of red paeony root, rhizoma polygonati, radix astragali, herba cistanches and rhizoma acori graminei through a TCMSP database (https:// tcmspw.com/tcmsp.php), wherein the component screening condition is OB more than or equal to 30%, DL more than or equal to 0.18, wherein the compound components of the radix polygoni multiflori and the leech are not recorded in the TCMSP database, the compound components are supplemented by using a Batman-TCM database (https:// bionet. Ncpsb.cn/Batman-TCM /), component targets with the score of more than 20 are selected and included, all targets are corrected by an uniglot database (https:// www.uniprot.org /), and after non-human targets are removed, 29 compound components and 94 targets are obtained from the red paeony root; the rhizoma polygonati obtains 12 compound components and 86 targets; the astragalus root obtains 20 compound components and 194 targets; cistanche deserticola obtains 7 compound components and 158 targets; the grassleaf sweelflag rhizome obtains 4 compound components and 77 targets; the polygonum multiflorum obtains 16 compound components and 203 targets;
(2) Wien diagram:
inputting the screened drug targets and disease targets into Wen graph making software Venny 2.1 to obtain 90 common targets, and performing the following path enrichment analysis as predicted targets of drugs acting on the diseases, as shown in figure 1;
(3) PPI network construction:
inputting a drug disease common target point into a String database (https:// String-db. Org/cgi/input. Pl) to construct a PPI network, setting a biological type as 'Homo sapiens', and obtaining the PPI network, wherein the PPI network is provided with 90 nodes, 396 sides and an average degree value of 8.9, as shown in figure 2 (figure 2 is a PPI network diagram derived from a String website, figure 3 is a PPI network diagram drawn by cytoscape software, wherein the node color and the size in figure 3 are adjusted according to the degree value, the larger the color is, the deeper the degree value is, the thickness of a line is shown from large to small from thick to thin);
(4) Topology analysis:
leading a PPI network into a Cystonscape 3.8.0, carrying out topology analysis by a network analyzer tool, selecting genes with scores larger than average score as key targets by deviee sequencing, screening out 31 key targets in total, carrying out picture drawing on the 31 targets by using R4.0.3, and taking the abscissa as the degree value of each target, wherein the degree value is shown in fig. 4;
(5) Component-disease target network construction:
in order to better understand the complex action relationship among the components, the diseases and the corresponding targets, a component-disease-target network diagram is constructed based on the included components, the treatment diseases and the action targets, and the network diagram is drawn in a cytoscape3.8.0, as shown in fig. 5;
(6) And (3) screening key components:
introducing the component-disease target network diagram into a cytoscape3.8.0 for topology analysis, and sequencing the components, wherein the higher the delay value is, the more important the components are, as shown in a table 7 (the components with the average value larger than the average value can be selected as key components for subsequent study);
TABLE 7
(7) GO enrichment analysis:
carrying out GO biological process (biological process, BP), molecular function (molecular function, MF) and Cell Component (CC) enrichment on the drug disease common target, referring to a String database, screening items with corrected P value less than 0.05, and enriching to 1422 biological processes in total, wherein 105 molecular functions are related and 25 cell components are related;
(8) KEGG pathway enrichment:
performing KEGG path enrichment analysis on the drug disease common target, referring to a String database, screening items with corrected P value less than 0.05, enriching to 57 signal paths in total, using R4.0.3, and performing histogram drawing after installing and referring to a clusterifier package to obtain a result shown in figure 6;
(9) Component-disease-pathway-target network construction:
the component-disease-path-target network file is imported into a cytoscape3.8.0 to draw a path network diagram, so that the multi-component-multi-target action characteristics of the active components of the traditional Chinese medicine in the disease treatment process are more intuitively displayed, and the diagram is shown in figure 7.
The traditional Chinese medicine composition prepared by the embodiment of the invention can act on PPARG, EGFR, JUN, FOS, MYC and other multi-target spots through active ingredients such as quercetin, crocin, resveratrol, ursolic acid, stigmasterol and the like, activate breast cancer, PPAR signal paths, MAPK signal paths, EGFR tyrosinase inhibitor resistance, PI3K-AKT and other signal paths to play a role in treating breast cancer, and further make clear that the traditional Chinese medicine composition plays an anti-tumor role through multi-target spot regulation and control of the multi-path.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, and alternatives falling within the spirit and principles of the invention.
Claims (9)
1. The traditional Chinese medicine composition for assisting breast cancer chemotherapy is characterized by comprising the following raw materials in parts by weight: 45-55 parts of astragalus membranaceus, 10-15 parts of cistanche deserticola, 10-20 parts of wine glossy privet fruit, 10-20 parts of rhizoma polygonati, 6-10 parts of leech, 10-20 parts of rhizoma acori graminei, 10-15 parts of red paeony root, 10-15 parts of prepared polygonum multiflorum and 6-10 parts of honey-fried licorice root.
2. The traditional Chinese medicine composition for assisting breast cancer chemotherapy according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 50-55 parts of astragalus membranaceus, 12-15 parts of cistanche deserticola, 15-20 parts of wine glossy privet fruit, 15-20 parts of rhizoma polygonati, 8-10 parts of leech, 15-20 parts of rhizoma acori graminei, 10-12 parts of red paeony root, 10-12 parts of prepared polygonum multiflorum and 6-8 parts of honey-fried licorice root.
3. The traditional Chinese medicine composition for assisting breast cancer chemotherapy according to claim 2, which is characterized by comprising the following raw materials in parts by weight: 50 parts of astragalus, 15 parts of cistanche, 20 parts of wine glossy privet fruit, 20 parts of rhizoma polygonati, 10 parts of leech, 15 parts of grassleaf sweetflag rhizome, 10 parts of red paeony root, 10 parts of prepared tuber fleeceflower root and 6 parts of honey-fried licorice root.
4. A method for preparing a traditional Chinese medicine composition for assisting breast cancer chemotherapy according to any one of claims 1-3, comprising the following steps:
mixing rhizoma Acori Graminei, pulverizing, and sieving to obtain rhizoma Acori Graminei powder;
soaking radix astragali, herba cistanches, fructus Ligustri Lucidi, rhizoma Polygonati, hirudo, radix Paeoniae Rubra, radix Polygoni Multiflori Preparata, and radix Glycyrrhizae Preparata in water, decocting twice, mixing the decoctions, concentrating under reduced pressure to soft extract, and drying under reduced pressure to obtain dry extract;
mixing rhizoma Acori Graminei powder and dry extract with dextrin, pulverizing, and sieving.
5. The method for preparing a Chinese medicinal composition for assisting breast cancer chemotherapy according to claim 4, wherein in the step of soaking astragalus, cistanche, glossy privet fruit, rhizoma polygonati, leech, red paeony root, prepared polygonum multiflorum and honey-fried licorice root in water, the soaking time is 0.5-1h.
6. The method for preparing a Chinese medicinal composition for assisting breast cancer chemotherapy according to claim 4, wherein in the step of decocting twice, 8-15 times of water is added in the first decoction, 1.5-2h is decocted, 6-12 times of water is added in the second decoction, and 1.5-2h is decocted.
7. The method for preparing a Chinese medicinal composition for assisting breast cancer chemotherapy according to claim 4, wherein in the step of concentrating under reduced pressure to obtain a thick paste, the temperature of the reduced pressure concentration is 50-60 ℃, and the relative density of the thick paste is 1.25-1.4.
8. The method for preparing a traditional Chinese medicine composition for assisting breast cancer chemotherapy according to claim 4, wherein in the step of drying under reduced pressure to obtain dry extract, the temperature of the drying under reduced pressure is 60-80 ℃.
9. An application of the Chinese medicinal composition for assisting breast cancer chemotherapy according to any one of claims 1-3 in preparing medicines for improving effective rate of breast cancer new assisting chemotherapy, reducing bone marrow suppression and improving immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311000052.4A CN116712507B (en) | 2023-08-10 | 2023-08-10 | Traditional Chinese medicine composition for assisting breast cancer chemotherapy and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311000052.4A CN116712507B (en) | 2023-08-10 | 2023-08-10 | Traditional Chinese medicine composition for assisting breast cancer chemotherapy and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116712507A true CN116712507A (en) | 2023-09-08 |
| CN116712507B CN116712507B (en) | 2023-10-20 |
Family
ID=87871985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311000052.4A Active CN116712507B (en) | 2023-08-10 | 2023-08-10 | Traditional Chinese medicine composition for assisting breast cancer chemotherapy and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116712507B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001066123A2 (en) * | 2000-03-09 | 2001-09-13 | Yale University | Composition consisting of phy906 and chemotherapeutic agents |
| CN102058805A (en) * | 2010-11-14 | 2011-05-18 | 耿平 | Oral medicine for preventing and treating leukocytopenia caused by chemotherapy |
| CN103053908A (en) * | 2013-01-22 | 2013-04-24 | 山西大学 | Functional food capable of rising white blood cells and preparation method thereof |
| CN105435206A (en) * | 2016-01-24 | 2016-03-30 | 朱晓婷 | Traditional Chinese medicine preparation for preventing and treating bone marrow suppression after radiotherapy and chemotherapy |
| CN109939191A (en) * | 2019-04-04 | 2019-06-28 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Chinese medicine composition, preparation method and the application of bone marrow suppression after a kind of antagonism chemotherapy of tumors |
| CN110269924A (en) * | 2019-07-22 | 2019-09-24 | 左俊岭 | A kind of Chinese medicine composition and its preparation method and application for preventing and treating tumour chemoradiotherapy and targeting leukopenia caused by medicine |
-
2023
- 2023-08-10 CN CN202311000052.4A patent/CN116712507B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001066123A2 (en) * | 2000-03-09 | 2001-09-13 | Yale University | Composition consisting of phy906 and chemotherapeutic agents |
| CN102058805A (en) * | 2010-11-14 | 2011-05-18 | 耿平 | Oral medicine for preventing and treating leukocytopenia caused by chemotherapy |
| CN103053908A (en) * | 2013-01-22 | 2013-04-24 | 山西大学 | Functional food capable of rising white blood cells and preparation method thereof |
| CN105435206A (en) * | 2016-01-24 | 2016-03-30 | 朱晓婷 | Traditional Chinese medicine preparation for preventing and treating bone marrow suppression after radiotherapy and chemotherapy |
| CN109939191A (en) * | 2019-04-04 | 2019-06-28 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Chinese medicine composition, preparation method and the application of bone marrow suppression after a kind of antagonism chemotherapy of tumors |
| CN110269924A (en) * | 2019-07-22 | 2019-09-24 | 左俊岭 | A kind of Chinese medicine composition and its preparation method and application for preventing and treating tumour chemoradiotherapy and targeting leukopenia caused by medicine |
Non-Patent Citations (5)
| Title |
|---|
| 崔艺馨 等: "黄芪四君子汤治疗乳腺癌癌因性疲乏的疗效及机制：基于94例临床随机对照试验和网络药理学", 《J SOUTH MED UNIV》, vol. 42, no. 5, pages 649 - 657 * |
| 李俊玉, 崔学峰, 梁椿蕾: "升血汤防治化疗后骨髓抑制观察", 实用中医药杂志, vol. 16, no. 06, pages 48 * |
| 王一安;刘鹏熙;: "乳腺癌术后辅助化疗期间中医药参与治疗的作用及评价", 中医研究, no. 11, pages 58 - 60 * |
| 王迎红, 王怀璋, 余永虎: "中药对癌症化疗后骨髓保护作用的临床观察", 河南中医药学刊, no. 06, pages 64 - 65 * |
| 黄广培;: "中医药治疗乳腺癌化疗后骨髓抑制30例体会", 时珍国医国药, no. 09, pages 2256 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116712507B (en) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111437355A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| US20070082075A1 (en) | Traditional chinese medicine preparation for treatment of tumor and method of making and using same | |
| CN109464634A (en) | A kind of tonifying lung disperse accumulation particle and its preparation method and application | |
| CN116712507B (en) | Traditional Chinese medicine composition for assisting breast cancer chemotherapy and preparation method and application thereof | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN110339276B (en) | Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof | |
| CN115998815A (en) | Traditional Chinese medicine composition for delaying atherosclerosis and renal insufficiency progression and application thereof | |
| WO2022242173A1 (en) | Traditional chinese medicine for treatment of diabetic nephropathy | |
| CN108743781A (en) | A kind of anticancer drug and preparation method thereof | |
| CN105147996B (en) | Kidney-tonifying marrow-benefiting hematogenesis prescription and preparation method of paste and granules thereof | |
| CN108452173B (en) | Traditional Chinese medicine compound for treating idiopathic pulmonary fibrosis and preparation method and application thereof | |
| CN101062374B (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN1116868C (en) | Concentrated granule medicine of famous decoction formulation and its preparation | |
| CN102961656A (en) | Chinese medicinal composition for treating pulmonary fibrosis and its application | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN112138084A (en) | Traditional Chinese medicine formula for treating bronchiectasis syndrome of qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN101020026B (en) | Honeyed Guiqi ointment for enhancing body's resistance and its preparation | |
| CN113318174B (en) | Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN114917310B (en) | Traditional Chinese medicine for treating 3-5 stages of chronic kidney disease and preparation method thereof | |
| CN103301278B (en) | Traditional Chinese medicine preparation and application thereof | |
| CN117919368A (en) | Composition for treating lung cancer and application thereof | |
| CN116920066B (en) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof | |
| CN110201133B (en) | Traditional Chinese medicine composition for treating MRD | |
| CN117244016A (en) | Traditional Chinese medicine composition for preventing and treating cancer-induced fatigue and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |